Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Tectonic Therapeutic: Stock Spikes On Heart Failure Data -- Why I See Further Upside
Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...
Le Lézard3h
Azenta Announces the Election of Dipal Doshi to its Board of Directors
Azenta, Inc. today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics and a recognized leader in the biotechnology and pharmaceutical industries, has been elected to its Board ...
Investors Chronicle7h
A pharma stock emerging from Novo Nordisk's shadow
Luckily, the hiring process proceeded smoothly and Charles van Zyl joined as chief executive from Belgian pharma company UCB (BE:UCB) in 2023, while Joerg Hornstein has been in post as chief finance ...
Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Tectonic jumps on positive data from early-stage trial for lead asset
Tectonic Therapeutic (TECX) stock surges on positive interim data from Phase 1b trial for lead candidate TX45 in patients ...